お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:Frost Radar:心房細動(AFib)向け医療機器市場 - 2020年
市場調査レポート
商品コード
954119

Frost Radar:心房細動(AFib)向け医療機器市場 - 2020年

Frost Radar: Medical Devices in Atrial Fibrillation Market, 2020

出版日: | 発行: Frost & Sullivan | ページ情報: 英文 53 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.20円
Frost Radar:心房細動(AFib)向け医療機器市場 - 2020年
出版日: 2020年08月05日
発行: Frost & Sullivan
ページ情報: 英文 53 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、心房細動(AFib)情勢の新興動向について分析し、革新的なソリューションを提供し、主要なセグメントでリーダーシップを維持する主要企業について、プロファイルを紹介します。

AFibは、脳卒中を引き起こす血栓の最大の原因で、致命的な脳卒中を患う可能性が5倍高くなります。AFibの有病率は一般人口の約3%で、今後30年間で2倍になると予想されています。AFibを診断および治療するための医療機器の市場規模は、2025年に約150億米ドルに達すると予想されています。

目次

戦略的必須事項と成長環境

  • 戦略的必須事項
  • 成長環境

Frost Radar

  • Frost Radar:心房細動向け医療機器市場
  • Frost Radar:競合環境

C2A (主要企業)

  • Abbott Laboratories
  • AliveCor
  • AtriCure
  • Baylis Medical
  • Biosense Webster (Johnson & Johnson)
  • Biotronik
  • Boston Scientific
  • Cardiofocus
  • Eko Health
  • Firstbeat Technologies
  • iRhythm Technologies
  • Japan Lifeline
  • Medtronic
  • Microlife AG
  • Microport Scientific
  • MyDiagnostick Medical (Applied Biomedical Systems)
  • Occlutech
  • Omron
  • Osypka AG
  • Philips
  • Stereotaxis
  • Vital Connect
  • Zenicor

戦略的考察

  • 戦略的考察

次なるステップ:Frost Radarを活用して主要ステークホルダーを支援

  • Frost Radarの重要性
  • Frost RadarがCEOの成長チームを支援
  • Frost Radarが投資家を支援
  • Frost Radarが顧客を支援
  • Frost Radarが取締役会を支援

Frost Radarアナリティクス

  • Frost Radar:将来の成長可能性をベンチマーキング
  • 免責事項
目次
Product Code: K4BB-54

Benchmarking Future Growth Potential

This Frost Radar™ analyzes emerging trends in the atrial fibrillation (AFib) landscape and profiles key market participants that deliver innovative solutions and maintain leadership in major segments in the care continuum, such as screening and monitoring, image-guided navigation and cardiac mapping, cardiac ablation, and left atrial appendage (LAA) occlusion.

AFib is the top cause of blood clots that lead to stroke, and persons with the condition are five times more likely to suffer a fatal stroke. The prevalence of AFib is about 3% of the general population and is expected to double over the next 30 years. The estimated market size of medical devices to diagnose and treat AFib is expected to reach about $15 billion in 2025. Abbot, Biosense Webster (J&J), Boston Scientific, and Medtronic lead the market for minimally invasive intervention for diagnosis and surgical treatment by offering a plethora of electrophysiological diagnostic and interventional devices. However, the market for screening and monitoring is witnessing the emergence of disruptive start-ups building clinical-grade personal ECG devices with superior specificity and sensitivity parameters. The increase in the number of catheter-based procedures and the introduction of technologically advanced cardiac ablation devices are expected to drive growth for EP ablation segment. Novel catheter-based technologies, such as contact force sensing, pulsated field ablation (PFA) and titratable laser energy are expected to gain more adoption in cardiac ablation procedures. Advanced 3D cardiac mapping and robotic navigation systems from Philips and Stereotaxis are making ablation procedures quicker and efficient. There is increasing collaboration between companies specializing in ablation segment and those specializing in cardiac mapping and navigations. Similarly, established device companies are likely to create synergistic partnerships with or strategically acquire emerging start-ups in the screening segment to keep pace with technological advancement and create a pipeline of cutting-edge products. The screening segment is expected to show higher growth in the care continuum due to greater emphasis on early detection and remote monitoring through clinically validated handheld devices and patches. Companies, such as AliveCor and iRhythm Technologies, have disrupted the screening and monitoring of heart rate variability (HRV) by making more compact and user-friendly devices, in addition to building robust data analytics for an accurate diagnosis.

The Frost Radar™ reveals the market positioning of companies in an industry using their growth and innovation scores as highlighted in the Frost Radar™ methodology. The document presents the competitive profiles of each of the companies and provides insight into their innovation capabilities, growth potential, and future roadmap. Frost & Sullivan analyzes hundreds of companies in the industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned. Industry leaders on both the growth and innovation indices are recognized as best practice recipients.

Table of Contents

Strategic Imperative and Growth Environment

  • Strategic Imperative
  • Strategic Imperative (continued)
  • Growth Environment
  • Growth Environment (continued)
  • Growth Environment (continued)
  • Growth Environment (continued)

Frost Radar™

  • Frost Radar™: Medical Devices in Atrial Fibrillation Market
  • Frost Radar™: Competitive Environment
  • Frost Radar™: Competitive Environment (continued)

Companies to Action

  • Abbott Laboratories
  • AliveCor®
  • AtriCure
  • Baylis Medical
  • Biosense Webster (Johnson & Johnson)
  • Biotronik
  • Boston Scientific
  • Cardiofocus
  • Eko Health
  • Firstbeat Technologies
  • iRhythm Technologies
  • Japan Lifeline
  • Medtronic
  • Microlife AG
  • Microport Scientific
  • MyDiagnostick Medical (Applied Biomedical Systems)
  • Occlutech
  • Omron
  • Osypka AG
  • Philips
  • Stereotaxis
  • Vital Connect
  • Zenicor

Strategic Insights

  • Strategic Insights

Next Steps: Leveraging the Frost Radar™ to Empower Key Stakeholders

  • Significance of Being on the Frost Radar™
  • Frost Radar™ Empowers the CEO's Growth Team
  • Frost Radar™ Empowers Investors
  • Frost Radar™ Empowers Customers
  • Frost Radar™ Empowers the Board of Directors

Frost Radar™Analytics

  • Frost Radar™: Benchmarking Future Growth Potential
  • Frost Radar™: Benchmarking Future Growth Potential
  • Frost Radar™: Benchmarking Future Growth Potential
  • Legal Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.